CD274 and cancer: Because identifying erasable and therapy-resistant tumor clones can be difficult, and since predicating when cancer might recur in “cured” subjects equally lacks precision, upregulation of PD-L1 may be viewed as a reliable, assayable theranostic and mechanistic biomarker.